Clinical trials
Lung clinical trials
Below are recruiting lung clinical trials, each written for real people, not researchers. We’re tracking 2,885 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04585490RecruitingPhase 3
Testing a personalized add-on treatment after stage III lung cancer
This phase 3 trial tests whether tailoring the next (add-on) treatments can improve outcomes after standard chemoradiation and immunotherapy for stage III, unresectable (not operable) non-small cell lung cancer. It specifically looks at giving durvalumab plus an additional drug (tremelimumab) and possibly other consolidation chemotherapy based on a personalized plan.
Stanford, CaliforniaAges 18 years+ - NCT04591002RecruitingPhase 2
Osimertinib after lung cancer surgery to slow new lung spots
This trial studies osimertinib, a targeted medicine, after surgery to help stop lung cancer from growing or spreading. It’s for people with an early lung cancer that has EGFR mutations and leftover “ground-glass” lung spots in another area.
Seoul, KangnamguAges 30–75 - NCT04606446RecruitingPhase 2
Study drug for ER-positive, HER2-negative cancers after treatment
This Phase 2 study tests a new Pfizer medicine (PF-07248144) for certain advanced or metastatic breast, prostate, or lung cancers that have not responded to standard treatment or no standard options exist. You may qualify if you have a specific tumor type and a limited number of prior cancer treatments, and if your body functions (blood, liver, kidneys) and heart rhythm meet safety limits.
Scottsdale, ArizonaAges 18 years+ - NCT04611867Recruiting
Test “BetterEveryDay” patient-reported care for pancreatic or bile cancer
This study studies how a patient “reporting” program (called PRO) works for people with advanced pancreatic or bile-tract cancer. It may help teams understand symptoms and needs earlier to improve care and support during treatment.
HerlevAges 18 years+ - NCT04624373Recruiting
Test tumor DNA from breath biopsy samples
This study checks tiny pieces of DNA from a sample taken during a breathing-tube biopsy (EBUS-TBNA) to better identify certain lung cancer changes. It may help doctors learn more about the type of lung cancer and, in some cases, why targeted treatments stop working.
ToulouseAges 18–65 - NCT04631770Recruiting
Mediastinal node removal versus sparing nodes for early lung nodule
This trial compares two surgical approaches for people with a single small, noncancer-looking lung nodule (a GGN) that is diagnosed as very early lung cancer. It aims to see whether removing mediastinal lymph nodes—or leaving them alone—can lead to better outcomes with less harm.
Tianjin, Tianjin MunicipalityAges Any age - NCT04644094Recruiting
Dexamethasone for heart function after very early birth
This study looks at how giving a steroid medicine (dexamethasone) after very early birth affects the baby’s heart function. It may help doctors better understand risks and benefits for babies who need treatment for serious lung problems.
Montreal, QuebecAges 1 minute+ - NCT04644952Recruiting
Study of robotic lung segment surgery outcomes
This study looks at people who had a lung surgery called a segmentectomy with robotic assistance in the past. It aims to understand how these surgeries are done over time and what outcomes result for patients.
Houston, TexasAges Any age - NCT04657042Recruiting
4D MRI scans to guide lung or liver cancer radiation
This trial tests whether special “4D” MRI scans can improve precision radiation planning for people with lung or liver cancer. You may get MRI scan data to better account for tumor movement, alongside your usual radiation treatment.
Charlottesville, VirginiaAges 18–82 - NCT04677205Recruiting
Tumor-to-lymph-node study after lung cancer surgery
This study looks at molecular (biologic) signals in the tumor and nearby lymph nodes after curative surgery for stage IIIA lung cancer. It may help doctors better understand the disease and improve future treatment planning.
BordeauxAges 18 years+ - NCT04678648RecruitingPhase 1
Testing RSC-1255 in advanced cancers with RAS changes
This early study (Phase 1) tests a new drug, RSC-1255, in people with advanced or metastatic cancers that have RAS mutations. It’s mainly focused on whether the treatment can be given safely and at what dose, and to see if it may shrink tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT04680377Recruiting
Using gut microbes to predict durvalumab side effects in lung cancer
This study looks at the microbiome (the tiny organisms in your gut) to try to predict who will get side effects from durvalumab after chemoradiation. If you join, your care team will use your microbiome results to help understand toxicity risk and improve future treatment planning.
Kansas City, KansasAges 18 years+ - NCT04686305RecruitingPhase 1
Test drug T-DXd plus immunotherapy, with or without chemotherapy for HER2+ lung cancer
This Phase 1 study tests the safety (and early effectiveness) of T-DXd combined with immunotherapy, sometimes also with chemotherapy, in people with advanced lung cancer that is HER2-positive. It may help if standard options have been limited or your tumor does not have certain genetic changes that already have targeted treatments.
Duarte, CaliforniaAges 18 years+ - NCT04700579Recruiting
Study lung changes before and after treatment for active TB
This study looks at changes in the lungs and immune system before TB treatment and again after treatment. By sampling lung fluid and comparing it over time, researchers hope to learn signatures that reflect how TB responds to care.
Cape Town, Western CapeAges 18–60 - NCT04701476RecruitingPhase 2
Pembrolizumab for advanced colorectal or lung cancer
This study tests pembrolizumab (an immune system medicine) with another treatment (TATE) in people with advanced colorectal or lung cancer that is not driven by certain gene changes. It may help shrink tumors after standard chemotherapy has stopped working.
Orange, CaliforniaAges 18 years+ - NCT04722835Recruiting
Study lung immune cells in people at risk for COPD
This study looks at different lung immune cell patterns and how they work in smokers who are not yet diagnosed with COPD or asthma. It may help researchers understand why some people are more likely to develop COPD, which could guide future prevention or early treatments.
San Francisco, CaliforniaAges 40–75 - NCT04777084RecruitingPhase 2
Lenvatinib plus PD-1 antibody for advanced lung cancer
This Phase 2 study tests whether a combination of lenvatinib and a PD-1/PD-L1–blocking antibody (IBI318) can shrink advanced non-small cell lung cancer and is safe to use. It targets people whose cancer has specific genetic changes or specific prior treatment history, based on three different study groups.
Changsha, HunanAges 18–75 - NCT04778046RecruitingPhase 2
Study lung pressure treatment for people waiting for transplant
This Phase 2 trial is for adults with pulmonary hypertension who are on the lung transplant waiting list at Duke. It aims to test whether the study treatment can improve lung pressure and related health outcomes, while using things like MRI to monitor changes.
Durham, North CarolinaAges 18 years+ - NCT04783168Recruiting
Using a step-tracking device to improve recovery after lung surgery
This study tests whether tracking daily steps with a wearable and app can help people recover better after lung surgery (especially a lobectomy). You may be asked to wear a device and follow a recovery plan while your activity is monitored.
Houston, TexasAges 18 years+ - NCT04787042RecruitingPhase 1/Phase 2
Safety and early benefits of ST-067 for advanced solid tumors
This early-stage trial tests ST-067 to see if it is safe and whether it may shrink advanced cancers. It also looks at how the drug moves through the body and affects the immune system.
Scottsdale, ArizonaAges 18 years+ - NCT04801108Recruiting
Lung valve treatment for emphysema with specific lung anatomy
This trial tests a one-way lung valve system to reduce over-inflated lung areas in people with emphysema. It’s aimed at patients whose lung scans suggest they may benefit from “fissure completion” to improve airflow.
Boston, MassachusettsAges 40–75 - NCT04807114Recruiting
Blood or tissue testing to find markers for lung cancer treatment
This study uses detailed “single-cell” testing to look for markers that can predict how well immunotherapy works and what side effects may happen. It is for people with non-small cell lung cancer starting standard first-line treatment.
LeuvenAges 18–120 - NCT04808596Recruiting
Pulmonary hypertension registry and blood sample study
This study builds a registry and collection system for people with pulmonary hypertension, confirmed by a specific heart test. By joining, you help researchers learn more about the condition and may support future studies.
Kansas City, KansasAges 18 years+ - NCT04842812RecruitingPhase 1
Personalized immune cell therapy for advanced solid tumors
This Phase 1 study tests engineered immune cells (TILs/CAR-TILs) made from your tumor to treat advanced solid cancers that have not responded to standard treatments. It may help your immune system better recognize and attack the cancer, but it is mainly focused on safety and early results.
GuangzhouAges 18–85
Hear when a new Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung?
- Yes. Clin2 currently lists 2,885 recruiting lung studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.